EP0190296A1 - Opiate antagonists - Google Patents
Opiate antagonistsInfo
- Publication number
- EP0190296A1 EP0190296A1 EP19850904076 EP85904076A EP0190296A1 EP 0190296 A1 EP0190296 A1 EP 0190296A1 EP 19850904076 EP19850904076 EP 19850904076 EP 85904076 A EP85904076 A EP 85904076A EP 0190296 A1 EP0190296 A1 EP 0190296A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- general formula
- compound
- group
- opiate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
Definitions
- This invention relates to the identification and isolation of compounds having opiate receptor binding activity, to the synthesis thereof, and to the use of such compounds as opiate narcotic antagonists.
- R, , R 2 and R_ groups represents a feruloyl or isoferuloyl group of the formula II or III, respectively:
- R.. , R_ and R-. are as defined above.
- Feruloylquinic acids of the general formula IV are known to occur in green coffee beans (Clifford, M.N. , Food Chem. 4, 146-149 (1961) ) .
- Compounds of the general formula I may also be isolated directly from coffee beans which have been roasted, ground and extracted with water and from instant coffee. This process, which includes thes teps of adsorption on an ion exchange resin followed by chromatography to isolate fractions having the desired activity, is described in greater detail below.
- the present invention also provides a process for the preparation of the compounds of the general formula I, above, which process comprises the reaction of quinic- 1,3-lactone (or quinide) of the formula V:
- each R separately represents H or a removable hydroxy protecting group, with a ferulic or isoferulic acid of the formula VI or VII, respectively:
- R. is an acetyl or other hydroxy protecting group, or a reactive derivative thereof, followed by removal of the group R. and, if necessary any hydroxy
- the lactone of the formula V may be prepared from quinic acid by reaction with a condensing agent, for example dicyclohexylcarbodiimide (DCC) , or by other known methods, such as by reaction with gaseous HCl in acetone.
- a condensing agent for example dicyclohexylcarbodiimide (DCC)
- DCC dicyclohexylcarbodiimide
- Removable hydroxy protective groups R may be added by methods known per se in the art.
- acetylferuloylquinides or acetylisoferuloylquinides the acetyl group is removed by brief exposure to methanolic K 2 C0 3-
- the process of the invention involves the reaction of quinic-1,3-lactone of the formula
- R. is an acetyl or other hydroxy protecting group, followed by removal of the group R.. Similarly, the protecting isopropylidene or trichloroethoxy carbonyl groups are removed to give in the cases of VA, VB, and VC, the 1,5, and 4-substituted esters of quinic-l,3-lactone respectively.
- Compounds of the general formula I exhibit significant opiate receptor binding activity, and thus have potential for use as opiate antagonists in reversing the toxic effects of opiate narcotic analgesics such as morphine, for example in the treatment of opiate narcotic overdosage and in the reversal of respiratory depression following the use of narcotics during surgery.
- opiate narcotic analgesics such as morphine
- the present invention therefore also extends to pharmaceutical compositions comprising a compound of the general formula I, together with one or more pharmaceutically acceptable carrier or diluent; as well as to methods of treatment of the conditions outlined above, which comprise administration to a patient of a compound of the general formula I, or a pharmaceutical composition containing a compound of the general formula I.
- GC-MS gas chromatogram-mass spectra
- Principal total ion peaks of the gas chromatogram contained M/Z 249 (derivatized feruloyl ions) and five of these also exhibit the same molecular ion M/Z 566.
- the five, with similar mass spectra, are from the possible feruloylquinides of general formula I. Some may be cis-isomers produced as artifacts by the conditions during gas chromatography.
- Another five hidden peaks of derivatized caffeoyl ions M/Z 307, totalling 10% of the feruloyl ions were also observed and were assumed to represent demethylation that occurred during isolation.
- Conversion of the roasted bean to instant coffee is estimated to double the concentration of active quinides - possibly to 2% of instant coffee. If this figure is applied to - the ED 50 for instant coffee set out in Table 1 (1.2 mg/ml) it would indicate that feruloylquinides have an ED 5Q of 0.024 mg/ml. The finding of 0.05 mg/ml for crude feruloylquinides indicates that one or more of the isomeric forms of feruloylquinide produce the predominant opiate receptor binding activity of instant coffee.
- ED-.'s represent the concentration of material required to displace by 50% the binding of 3 H-naloxone in a crude rat brain membrane preparation as described in detail hereinafter. Samples were dissolved in 0.05 M Tris (HCl buffer at pH 7.4 and assayed in triplicate' at 3 to 5 concentrations. ED-, values are determined graphically on log transformed data.
- Figure 2 shows mass chromatograms of (A) TMS derivatives of instant coffee extract (Fig.l) showing time profiles of total ion current, ions m/z 249 (feruloyl ion), and m/z 566 and (b) TMS derivatives of 4- and 5-caffeoylquinides showing time profiles of total ion current, ion m/z 307 (caffeoyl ion) , and m/z 624 (M+) .
- Derivatives were prepared by reaction of sample with 100 ⁇ l trimethylsilylimidazole (Pierce) and
- the receptor assay system was based on that of Pert and Snyder (Pert, C.B. & Snyder, S.H., Proc. Natu. Acad. Sci. U.S.A. 70, 2243-2247, (1973) ).
- Male Sprague-Dawley rats were killed by decapitation, and brains minus cerebellum homogenized in 25x vol of 0.05 Tris-HCl, pH 7.4 buffer using a Brinkmarin Polytron on setting 4 for 5 s. The homogenate was centrifuged for 20 min at 18,000 g, and the pellet resuspended in 25x vol buffer.
- Acetylferulic acid was prepared after the method of L.S.Fosdick & A.C.Starke, J.Am.Chem.Soc. 6J2, 3352-5 (1940).
- Acetylferuloylquinide from the previous preparation was dissolved in methanol and K ⁇ CO ⁇ dissolved in aq.methanol was added.
- acetylisoferulic acid prepared previously by J.Pacsu and C.Stieber, Ber. 62B, 2974-9 (1929)
- acetylisoferuloylquinides may be prepared exactly as described previously • for acetylferuloylquinides.
- the acetyl group may be removed by the method described previously to yield the 1-feruloyl ester of quinic-1,3-lactone.
- the 1-isoferuloyl ester of quinic-l,3-lactone may be prepared.
- Example 4 The general procedures of Example 4, may be repeated using 2,2,2-trichloroethoxycarboxy esters as protecting groups on the 1-, or 1- and 5-, hydroxy groups of quinic-1,3—lactone, following ' the methods for synthesis and facile hydrolysis described by T.B.Windolz and D.B.R.Johnston, Tetrahedron Lett. 2555 (1967) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composés de formule générale (I), où l'un des groupes R1, R2 et R3 représente un groupe féruloyle ou isoféruloyle de formule (II) ou (III), respectivement, et les autres groupes R1, R2 et R3 représentent l'hydrogène. Ces composés présentent une activité de récepteurs d'opiate et peuvent être utilisés dans le traitement des effets toxiques d'analgésiques narcotiques à base d'opiate. Est décrite la préparation de ces composés par extraction du café et par des procédés de synthèse.Compounds of general formula (I), where one of the groups R1, R2 and R3 represents a feruloyl or isoferuloyl group of formula (II) or (III), respectively, and the other groups R1, R2 and R3 represent hydrogen . These compounds exhibit opiate receptor activity and can be used to treat the toxic effects of opiate-based narcotic pain relievers. The preparation of these compounds is described by extraction of coffee and by synthetic methods.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU6761/84 | 1984-08-24 | ||
AU676184 | 1984-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0190296A1 true EP0190296A1 (en) | 1986-08-13 |
Family
ID=3697344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19850904076 Withdrawn EP0190296A1 (en) | 1984-08-24 | 1985-08-23 | Opiate antagonists |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0190296A1 (en) |
WO (1) | WO1986001508A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0581980T3 (en) * | 1992-08-03 | 1999-09-27 | Nestle Sa | 3- and / or 4-substituted quinic acid derivatives and methods for preparing 3- and / or 4-substituted quinic acid |
DE69228541T2 (en) * | 1992-08-03 | 1999-08-12 | Societe Des Produits Nestle S.A., Vevey | Quinic acid derivatives and process for the production of quinic acid derivatives |
BR0100444C1 (en) * | 2001-01-30 | 2003-12-02 | Laboratorios Biosintetica Ltda | Method of obtaining an extract with antidepressant and opioid antagonist properties and of pharmaceutical products obtained from it |
CA2347879A1 (en) | 2001-05-11 | 2002-11-11 | Vanderbilt University | Substituted dicinnamoylquinides and their use in augmentation of adenosine function |
US20060286238A1 (en) * | 2005-06-20 | 2006-12-21 | The Procter & Gamble Company | Processes for isolating bitter quinides for use in food and beverage products |
CN108003027B (en) * | 2017-12-25 | 2021-07-06 | 北京微医智慧信息技术有限责任公司 | 1-O-caffeoylquinic acid, its derivative, preparation method and use thereof |
-
1985
- 1985-08-23 WO PCT/AU1985/000200 patent/WO1986001508A1/en unknown
- 1985-08-23 EP EP19850904076 patent/EP0190296A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO8601508A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1986001508A1 (en) | 1986-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
King et al. | Chemistry of phytotoxins associated with Streptomyces scabies the causal organism of potato common scab | |
US4313946A (en) | Chemotherapeutically active maytansinoids from Trewia nudiflora | |
Iwu et al. | Dioscoretine: the hypoglycemic principle of Dioscorea dumetorum | |
Powell et al. | Novel maytansinoid tumor inhibitors from Trewia nudiflora: trewiasine, dehydrotrewiasine, and demethyltrewiasine | |
Ghedira et al. | Four cyclopeptide alkaloids from Zizyphus lotus | |
Hahn et al. | Hydroxycinnamic acid derivatives, caffeoylmalic and new caffeoylaldonic acid esters, from chelidonium majus*, 1 | |
King et al. | Isolation and characterization of thaxtomin-type phytotoxins associated with Streptomyces ipomoeae | |
EP0190296A1 (en) | Opiate antagonists | |
Lindsay | The alkaloids of Margaritaria indica. Part 2. The structures of 4-epiphyllanthine, margaritarine and the structural revision of securinol A | |
US4298525A (en) | Bis-indole-alkaloid | |
TAKEDA et al. | Studies on the bacterial gall of Myrica rubra: isolation of a new [7, 0]-metacyclophan from the gall and DL-β-phenyllactic acid from the culture of gall-forming bacteria | |
Gu et al. | Minor withanolides from Physalis philadelphica: structures, quinone reductase induction activities, and liquid chromatography (LC)-MS-MS investigation as artifacts | |
Rasheed et al. | Hirsutine: A new alkaloid from Cocculus hirsutus | |
Chatterjie et al. | Isolation and stereochemical identification of a metabolite of naltrexone from human urine | |
Pelletier et al. | Alkaloids of Delphinium barbeyi | |
Hirai et al. | Isolation and structure elucidation of fecapentaenes-12, potent mutagens from human feces | |
Ferris et al. | Lythraceae alkaloids. VIII. Structure and stereochemistry of the biphenyl ether alkaloids from Decodon verticillatus | |
Thomas et al. | 15-(14'-eburnamyl) pleiocarpinine (pleiomutine). A new dimeric indole alkaloid from Pleiocarpa mutica Benth | |
Chimichi et al. | Complete assignment of the 1H and 13C NMR spectra of secoisolariciresinol diglucoside, a mammalian lignan precursor isolated from Linum usitatissimum | |
de Araújo-Júnior et al. | Alkaloids and diterpenes from Croton moritibensis | |
Lavie et al. | Trechonolide A, a new withanolide type from Trechonaetes laciniata | |
Costa et al. | Indole alkaloids from the roots of an African plant Securidaca longipedunculata. I. Isolation by column chromatography and preliminary structural characterization by mass spectrometry | |
Vecchietti et al. | Alkaloids of Ocotea acutangula | |
EP3255031B1 (en) | Compound, and separation method, synthesis method and use thereof | |
Speranza et al. | Isolation and chemical characterization of a new constituent of Cape Aloe having the 1, 1-diphenylethane skeleton |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE FR GB IT LI NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19860729 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RAE, IAN, DAVID Inventor name: WYNNE, KENNETH, NEVILLE Inventor name: FUNDER, JOHN, WATSON Inventor name: BOUBLIK, JAROSLAV, HAMAN Inventor name: DRUMMER, OLAF, HEINO |